NCT02906514已完成3 期
Priming of Cardiopulmonary Bypass With Hydroxyethyl Starch 130/0.4 or Sodium Chloride 0.9% : a Double Blind Randomized Pilot Study in Adult Elective Conventional Cardiac Surgery
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Supplementary volume of fluid administered during cardiopulmonary bypass (ml)
研究概览
简要总结
Best priming for cardiopulmonary bypass in cardiac surgery is unknown. Efficacy and toxicity of Hydroxyethyl Starch 130/0.4 used in this context are uncertain.
The aim of this pilot study is to determine if Hydroxyethyl Starch 130/0.4 is more effective than Sodium Chloride 0.9% in short term hemodynamic purpose without side renal or hemostatic effect.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients scheduled for elective conventional cardiac surgery with cardiopulmonary bypass
- •Patients insured under the French social security system
排除标准
- •Pregnancy
- •Patients placed under guardianship
- •Urgent surgery
- •Cardiac surgery without cardiopulmonary bypass
- •Anterior cardiac surgery
- •Non conventional cardiac surgery (mini-invasive surgery, dual valve replacement, right heart surgery)
- •Simultaneous inclusion in another study with potential interference in outcomes
- •Heparin-induced thrombocytopenia
- •Chronic renal insufficiency (glomerular filtration rate < 60mL.min-1.m-2)
- •Nature/nurture hemostasis disorders, in particular Von Willebrand disease and hemophilia
- •Hydroxyethyl Starch allergy
- •Weight under 33 kg
- •Mechanical hemodynamic support at the end of the surgery
研究组 & 干预措施
Hydroxyethyl starch 130/0.4
Experimental
干预措施: Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius) (Drug)
Sodium Chloride 0.9%
Placebo Comparator
干预措施: Sodium Chloride 0.9% (Fresenius) (Drug)
结局指标
主要结局
Supplementary volume of fluid administered during cardiopulmonary bypass (ml)
时间窗: Day 1 (From initiation to separation of cardiopulmonary bypass)
Fluid administered during cardiopulmonary bypass for normal functioning, with the exception of blood product, cardioplegia and priming
次要结局
- Coagulation parameters : platelets(H24)
- Fluid balance(Hour 12)
- Sequential Organ Failure Assessment score(Hour 0)
- Acid-Base parameters : Chloremia(Hour 24)
- Delay for ablation of surgical drainage(Day of ablation of surgical drainage, 24 hours)
- Delay to first extubation (number of hours)(Hour of first extubation, an average of 5 hours)
- Hospital stay (number of days)(Day of hospital exit, an average of 7 days)
- Mortality of any cause(Day 90)
- Variation of preoperative hematocrit and lowest hematocrit during cardiopulmonary bypass(Day 1 (From initiation to separation of cardiopulmonary bypass))
- Acid-Base parameters : Lactatemia(Hour 24)
- Intensive care unit stay (number oh days)(Day of intensive care unit stay exit)
- Renal replacement therapy dependency(Day 90)
- Acid-Base parameters : arterial pH(Hour 24)
- Acid-Base parameters : Base Excess(H24)
- Coagulation parameters : activated partial thromboplastin(H24)
- Coagulation parameters : fibrinogen level(H24)
- Coagulation parameters : prothrombin(H24)
- Hemoglobin level(Hour 24)
- Surgical bleeding(during surgical drainage, an average of 24 hours)
- Revision surgery for bleeding(Hour 12)
- Antiemetic medication use(end of intensive care unit stay, 24 hours)
- Creatinine level variation(Day 90)
- Renal replacement therapy use during intensive care stay(end of intensive care unit stay, an average of 24 hours)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
不适用
Effects of Hypoxic-hyperoxic Preconditioning in Cardio-surgical PatientsMyocardial Reperfusion InjuryHypoxiaHyperoxiaCoronary Artery DiseaseNCT05354648Alexander Averyanov120
已完成
3 期
Impact of Hyperoxia During CardiopulmonaryCardiac ComplicationsNCT02819739Centre Hospitalier Universitaire, Amiens330
Unknown
不适用
Pancreaticoduodenectomy With or Without Preoperative Hyperbaric Oxygen TherapyPeriampullary TumorCommon Bile Duct NeoplasmsDuodenal NeoplasmsNCT02575014Florida Hospital Tampa Bay Division50
招募中
不适用
Hyperbaric Chamber and Cardiorespiratory Changesinflammation, infection, cellulitis, Vasculitis, osteomyelitis.C23.550.470C01.539C01.539.800.130C14.907.940C01.539.160.495RBR-3rp6tzniversidade do Sagrado Coração
招募中
2 期
A pilot study of preoperative Roxadustat in patients undergoing major surgery.Postoperative ComplicationsSurgical site infectionSurgery - Other surgeryInfection - Other infectious diseasesACTRN12624000188538Royal Perth Hospital150